Neuropace
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $19,256 | $18,124 | $18,012 | $16,427 |
Gross Profit | 14,134 | 13,343 | 13,545 | 12,233 |
EBITDA | -5,786 | -7,122 | -4,642 | -4,668 |
EBIT | -6,230 | -7,545 | -5,051 | -5,066 |
Net Income | -7,514 | -8,925 | -6,200 | -7,257 |
Net Change In Cash | 19,256 | 18,124 | 18,012 | 16,427 |
Free Cash Flow | -3,963 | -7,632 | -3,373 | -2,311 |
Cash | 12,844 | 12,998 | 18,058 | 9,717 |
Basic Shares | 28,853 | 28,285 | 26,799 | 26,017 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $65,421 | $45,520 | $45,183 | $41,138 |
Gross Profit | 48,122 | 32,493 | 33,435 | 30,272 |
EBITDA | -25,569 | -39,553 | -28,374 | -12,480 |
EBIT | -27,174 | -42,540 | -28,670 | -12,792 |
Net Income | -32,956 | -53,370 | -38,109 | -35,982 |
Net Change In Cash | 65,421 | 45,520 | 45,183 | 41,138 |
Cost of Revenue | -12,582 | -7,447 | ||
Free Cash Flow | -19,874 | -37,472 | -24,961 | -21,671 |
Cash | 18,058 | 6,605 | 19,187 | 26,390 |
Basic Shares | 25,851 | 24,594 | 24,452 | 23,828 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.26 |
2024-03-31 | -$0.32 |
2023-12-31 | -$0.23 |
2023-09-30 | -$0.28 |
